- Home
- ABLV vs OTLK Comparison
ABLV vs OTLK Comparison
Compare ABLV & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | OTLK |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | 89 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ABLV | OTLK |
|---|---|---|
| Price | $0.69 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 5.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,726.70 |
| Revenue Next Year | N/A | $80.34 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.38 |
| 52 Week High | $1.77 | $3.39 |
Technical Indicators
Market Signals| Indicator | ABLV | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 37.36 |
| Support Level | $0.60 | $0.39 |
| Resistance Level | $0.97 | $0.46 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 24.24 | 5.39 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.